[1] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[2] |
XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu.
Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652.
|
[3] |
ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang.
Progress on the pathological mechanism and treatment of frostbite
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
|
[4] |
BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong.
Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
|
[5] |
LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling.
Research progress on the antitumor activity of costunolide
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
|
[6] |
LI Miao, YU Qinwei, JIANG Zhenzhou, ZHANG Luyong, .
Regulatory mechanism of LDLR and research progress of its related diseases and drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 946-954.
|
[7] |
CHEN Jian, LAN Yu, WU Yong, SHEN Boxiong.
Effects of intestinal flora disturbance on postoperative cognitive dysfunction in patients with inhalation anesthesia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 639-644.
|
[8] |
TANG Jiawei, MENG Xiangzhe, SUN Xuemin, LI Yuexuan, LIU Xue, WEI Hong.
Role of vitamin D and ACE2 in COVID-19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1292-1298.
|
[9] |
CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin.
Advances in the study of iodine-resistant differentiated thyroid cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
|
[10] |
ZHOU Han, LIU Xiaodong.
Application of physiologically based pharmacokinetic model in drug development and several questions being thought
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 889-913.
|
[11] |
HAO Haiping.
Metabolic regulation and drug target discovery researches in China: Progress and prospect
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 955-963.
|
[12] |
ZHANG Quan, SHI Shiyuan, HAN Guihe.
1,25 dihydroxy vitamin D3 for immunoregulation in the treatment of spinal tuberculosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 787-793.
|
[13] |
CHEN Ying, YUAN Yonggui.
Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
|
[14] |
PEI Qinghua, SUN Jianli.
Research progress of Osimertinib acquired resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
|
[15] |
XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa.
Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
|